Investigator’s Brochure Writing: 5 Tips to Streamline Your SOC
Streamline developing a summary of changes for an Investigator’s Brochure, a document that summarizes the…
CertaraFebruary 19, 2025
How to Modernize Patient Narrative Writing
Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…
CertaraFebruary 12, 2025
12th Annual Cracow HTA Symposium
June 9-10, 2026 - Kraków - Join Europe’s leading HTA, payer, and policy experts. Explore EU…
CertaraFebruary 12, 2025
Certara’s Phoenix Platform – The world’s most trusted platform for PK/PD analysis and modeling
Today’s drug candidates are more complex than ever. But with development decisions on the line,…
CertaraFebruary 12, 2025
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies
This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…
CertaraFebruary 6, 2025
2025 cell and gene challenges: Scalability, supply chain and manufacturing
Explore insights on 2025 challenges in cell and gene therapy, including commercial viability, with expert…
CertaraFebruary 3, 2025
Best Practices for International Pharma Content Roll-Out
January 31, 2025 Pharmaceutical market access, sales, and field teams rely on high-quality, effective content…
CertaraJanuary 31, 2025
How do you see advances in personalized medicine reshaping patient care, and what are the key challenges and opportunities ahead?
Discover how advances in personalized medicine are reshaping patient care, and why biosimulation will become…
CertaraJanuary 31, 2025
Transforming Perspectives: 25 Years of PBPK Modeling in Drug-Drug Interactions
Vice President and Head of Global PK/PD and Pharmacometrics at Eli Lilly and Company Dr.…
CertaraJanuary 29, 2025
